NDAORALSOLUTION
Approved
Feb 2016
Lifecycle
Post-LOE
Competitive Pressure
35/100
Clinical Trials
20
Data completeness
5/8 — Partial
BRIVIACT (brivaracetam) by UCB Pharma is epoxide hydrolase inhibitors [moa]. First approved in 2016.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRIVIACT (brivaracetam) is an oral small-molecule antiepileptic agent approved in 2016 for seizure management. It works as an epoxide hydrolase inhibitor and is indicated for patients requiring adjunctive or monotherapy seizure control. The drug targets a mechanism distinct from first-generation anticonvulsants, offering an alternative for treatment-resistant epilepsy populations.
Post-LOEPost-LOE
Post-LOE positioning with moderate competitive pressure (35/100) suggests a stable but contracting commercial footprint; team sizes likely optimized for maintenance rather than growth.
Mechanism of Action
Epoxide Hydrolase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Started Jul 2024
120 enrolled
Childhood Absence EpilepsyJuvenile Absence Epilepsy
A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants
Started Mar 2024
64 enrolled
Healthy Study Participants
A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants
Started Apr 2022
24 enrolled
Healthy Study Participants
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Started Mar 2022
84 enrolled
Childhood Absence EpilepsyJuvenile Absence Epilepsy
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Started Jul 2021
153 enrolled
Childhood Absence EpilepsyJuvenile Absence Epilepsy
Worked on BRIVIACT at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.